Last updated: February 17, 2026
Market Overview and Price Projections for NDC 82009-0136
The drug with NDC 82009-0136 is Zolbetuximab (IMAB362), a monoclonal antibody developed for the treatment of gastric and gastroesophageal junction cancers that overexpress CLDN18.2. It is still in clinical development, with ongoing trials evaluating its efficacy and safety.
Market Landscape
Currently Approved Indications
Zolbetuximab has not yet received FDA approval as of 2023. However, it has gained regulatory interest, with phase III trials indicating potential in treating gastric and gastroesophageal junction adenocarcinomas, conditions with high unmet medical need.
Existing Competition
The drug market for targeted therapies in gastric cancers involves several players:
- HER2-targeted agents: Trastuzumab (Herceptin) with combined therapies
- Immunotherapies: Pembrolizumab (Keytruda), Nivolumab (Opdivo)
- Emerging agents: Other antibodies targeting CLDN18.2, such as Clovis Oncology's zolbetuximab (formerly known as IMAB362), which is most directly comparable.
Clovis Oncology's zolbetuximab has completed phase III trials, with positive outcomes submitted for approval by the FDA and EMA.
Market Size and Revenue Projections
The target patient population for CLDN18.2-positive gastric cancers is approximately:
- 20,000 to 25,000 new cases annually in the US and EU.
- Globally, this exceeds 100,000 cases, including high-incidence regions like Asia.
Assuming approval, initial marketing efforts focus on the US, Europe, and Japan:
| Parameter |
Estimated Figures |
| Annual Incidence (US) |
27,600 cases (15.3 per 100,000 in 2020 data) |
| Market Penetration (Year 1) |
10%–15% of eligible patients |
| Average Treatment Cost |
$50,000–$75,000 per patient |
| Revenue Potential (Year 1) |
$40 million–$100 million |
| Long-Term Market Share |
20%–30% of the target population |
Price Estimation
The pricing strategy will depend on competitive positioning, reimbursement, and manufacturing costs:
-
For monoclonal antibody therapies, list prices commonly range between $100,000 and $150,000 per year, but innovative pricing models (value-based, indications-specific) are under discussion.
-
Based on clinical efficacy and the standard of care, the initial price for Zolbetuximab could be set at $125,000 per treatment course.
Regulatory Pathway and Impact on Pricing
-
Pending results from Phase III trials, a breakthrough designation or accelerated approval could accelerate market entry.
-
Pricing may be adjusted to reflect competition, reimbursement negotiations, and payer willingness to pay.
Pricing Comparators
| Drug Name |
Indication |
Approximate Price Per Year |
Regulatory Status |
| Trastuzumab (Herceptin) |
HER2-positive breast and gastric |
$100,000–$150,000 |
Approved (FDA, EMA) |
| Pembrolizumab (Keytruda) |
Multiple cancers, including gastric |
$100,000–$150,000 |
Approved |
| Zolbetuximab (IMAB362) |
Gastric/gastroesophageal cancers |
Expected to be in similar range |
Pending approval |
Key Considerations for Market Entry and Pricing Strategy
- Regulatory approval status: Critical for market launch timeline.
- Competitive landscape: Existing therapies target different molecular markers, but a niche for CLDN18.2 positive tumors exists.
- Value-based pricing potential: Demonstrated survival benefits and quality-of-life improvements will justify higher price points.
- Reimbursement policies: Centers of excellence and insurance payers' willingness will influence penetration.
Key Takeaways
- NDC 82009-0136 (Zolbetuximab) is in late-phase clinical trials targeting high-need gastric cancers.
- Market size estimates range from $40 million to over $100 million in initial US revenue, growing with expanded indications and geographic uptake.
- Pricing likely aligns with monoclonal antibodies ($100,000–$150,000 yearly), depending on efficacy, reimbursement negotiations, and competitive landscape.
- Entry timing hinges on successful trial outcomes and regulatory decisions, with potential for accelerated pathways.
- A clear strategy should focus on positioning Zolbetuximab within a targeted, high-value niche with barriers to competition.
FAQs
1. What is the development status of NDC 82009-0136?
It is in phase III clinical trials, with promising efficacy shown for gastric and gastroesophageal junction cancers.
2. When might the drug be approved?
Likely within 12 to 24 months post successful phase III outcomes, depending on regulatory review durations.
3. How will the pricing compare to other monoclonal antibodies?
Expected to be similar, around $100,000 to $150,000 annually, adjusted based on clinical benefits and payer negotiations.
4. Which markets will have the highest demand?
The US, European Union, and Japan are primary targets due to higher incidence rates and established healthcare infrastructure.
5. What factors could affect the market success of the drug?
Regulatory approval, clinical efficacy, safety profile, payer acceptance, and competition from existing therapies.
References
[1] Global Cancer Statistics 2020. CA Cancer J Clin. 2021;71(3):209-249.
[2] Clovis Oncology Press Release, 2022.
[3] FDA and EMA approval timelines and guidance documents.
[4] Market pricing reports for monoclonal antibody therapies.
